|
Patient Safety/ Medical Error
Contributing journals to this collection:
JAMA & Archives Journals
Citations 231-240 of 525 total displayed.
- Health Agencies Update
Drug Safety
- Bridget M. Kuehn
JAMA 2008; 300: 2359-b.
[Extract]
[Full text]
[PDF]
- Commentaries
Benefits and Risks of Drug Treatments: How to Combine the Best Evidence on Benefits With the Best Data About Adverse Effects
- Jan P. Vandenbroucke; Bruce M. Psaty
JAMA 2008; 300: 2417-2419.
[Extract]
[Full text]
[PDF]
- Medical News & Perspectives
Groups Work to Boost Support for Vaccines
- Bridget M. Kuehn
JAMA 2008; 300: 2233-2235.
[Extract]
[Full text]
[PDF]
- Corrections
Incorrect Table Column Headings and Inaccurate Information in Text in: Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months
-
JAMA 2008; 300: 2252.
[Full text]
[PDF]
- Editor's Correspondence
No Black Box on Phosphosoda
- Michael Caswell
Arch Intern Med 2008; 168: 2285-a-2286-a.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Oral Sodium Phosphate Drug Products and Renal Function
- Kevin C. Abbott; Erin M. Bohen; Frank P. Hurst
Arch Intern Med 2008; 168: 2285.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Oral Sodium Phosphate and Renal Function—Reply
- Anand Khurana
Arch Intern Med 2008; 168: 2286-a-2287-a.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Oral Sodium Phosphate and Renal Function
- Lawrence B. Cohen
Arch Intern Med 2008; 168: 2286.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Participants in Phase 1 Oncology Research Trials Are Vulnerable
- Ron Berghmans
Arch Intern Med 2008; 168: 2287-2288.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Participants in Phase 1 Oncology Research Trials Are Vulnerable—Reply
- Christine Grady; Justine Seidenfeld; Elizabeth Horstmann; Ezekiel J. Emanuel
Arch Intern Med 2008; 168: 2288.
[Extract]
[Full text]
[PDF]
|
Advertisement


|
|
|